• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
171268 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
# y4 p0 N, o: [1 z* `# j; W& p# i
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ; T0 _( x* `- v9 \9 {3 x& h* y5 ^

  N5 d* ]1 S9 L" {% j" e3 L9 ?+ j* C( K% t* |# ~. t- l
Sub-category:. K8 h. i/ ~* T+ G; a0 w- J
Molecular Targets
5 r2 _# E* [. Z6 g: [4 J% j; I: e, _) V" q4 I$ m
4 n$ w. Q. @: k- j8 {
Category:
6 J$ \3 B- H" {- r/ n5 N6 `% rTumor Biology
" U! a. r! i0 I1 W* W1 v/ f' a, T  W

0 a8 V) d9 y$ I1 W$ u2 uMeeting:5 @. r; @$ h1 {5 Z
2011 ASCO Annual Meeting
! v* q! Q' l, }$ ~/ _, k
. Y9 h# n$ O2 R+ l( Z
  l% V/ I) t+ c, p) `Session Type and Session Title:2 E8 x2 N/ J" E: M! I9 b
Poster Discussion Session, Tumor Biology $ n! B6 J- C# [" {# I

  B4 U8 X) h& C5 P( r: `# U9 ]! m% J$ x+ V9 [/ H
Abstract No:" N9 ^* v% O5 ?& a7 Q9 o- s
10517 * m7 v/ ^3 N4 [0 P) o! m9 e/ u

/ r( \5 Q2 m9 b; E, P, d( f1 k% j: x+ k9 A
Citation:- r" o0 l, G, [, c$ e( ~1 j; c9 i
J Clin Oncol 29: 2011 (suppl; abstr 10517)
' _: T* l' E# Y) }& y9 ]
# x) ^# Q/ w+ a/ ~; g
- X" y; d, q: @! fAuthor(s):
  F9 C( d6 d, N0 B# LJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 S$ o% h0 Z/ f4 [$ ]4 G8 D
! ~6 v" I, t, g9 f  W0 }( y, Z3 o1 q* x/ O
3 S( A2 Y+ t$ b. I
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.8 ]- B2 T. _- F4 ]
, \9 X" \! k$ F
Abstract Disclosures' [# b) t" b! Q+ x" [

7 {1 c, r1 ~" l! _Abstract:
1 a* b) N$ @, k. _1 A
, S$ ~/ s# O/ A6 ]2 [# g. w, j+ T' ~9 s
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ i6 n( a+ D6 O' Y
, i: t: l6 s2 I- W# l) g! q% P
& N# t  p1 J: S' {( y  I
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
- W* W( W  m9 l( ]* Z2 f; B没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
2 K, N9 d1 }2 f
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ( n* R! p/ H: g3 x
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。: p! E4 k6 v2 i. T
ALK一个指标医院要900多 ...

- N, i( X% Z  S" i0 S+ X平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
: G4 M6 ]) a% |
, E+ E3 O4 D: p2 `' c6 T现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表